AJANTPHARMBSEAjanta Pharma LtdHighPositive
Announced Tue, 2 Jun · 10:29 IST

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 02, 2026 for Ravi Agrawal, trustee ....

Pledge ReleasedOwnership Changes View source PDF

AJANTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.4%1-day move
₹2940.70
prior close
₹2906.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.2-0.5-0.4-0.4+0.6+1.3+1.0+2.3+6.9+8.4+13.6
Up moveDown movePending
AI summary

Promoter Ravi Agrawal, through the Ravi Agrawal Trust, has disclosed both a release and a fresh creation of pledge on Ajanta Pharma shares under SEBI SAST Regulations. He released pledges on 2,60,000 equity shares — 1,60,000 with Aditya Birla Capital and 1,00,000 with Bajaj Finance — citing 'Excess Pledge' as the reason. Simultaneously, he created a fresh pledge of 2,20,000 shares with The South Indian Bank Ltd for re-financing purposes. On a net basis, pledged shares reduced by 40,000, taking post-event encumbered holding to 60,23,920 shares (4.82% of total share capital) against a promoter holding of 1,62,42,904 shares (13.00%).

Likely market impact

This is routine re-financing activity by the promoter — shares have not been sold, and overall promoter pledge burden has only marginally declined. No material impact expected on stock price; reassures investors that the promoter is actively managing debt rather than facing stress.